{
  "id": "adv_mhgap#screening_cues_b7ee2d86",
  "content": "The EML and EMLc includes products for MNS disorders\nComprehensive mental health action plan 2021–2030\nin the areas of psychotic disorders, mood disorders,\n(14), the Intersectoral global action plan on epilepsy\nanxiety, substance use and epilepsy (13,132). The\nand other neurological disorders 2022–2031 (3), the\nupdated recommendations for any psychotropic\nGlobal action plan on the public health response to\nmedicines will be used to inform the EML and EMLc\ndementia 2017–2025 (15), and the Global alcohol action\nand to promote affordable access to quality, safe and\nplan 2022–2030 (16).\neffective medicines for MNS disorders.\n16 https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre\n112\n5. Monitoring and evaluating\nthe impact of the guideline\nAfter the publication of this mhGAP guideline, where possible, including the Atlas: country resources\nWHO will continue to collect regular feedback from for neurological disorders (23), the Comprehensive\nimplementation activities to evaluate their usefulness mental health action plan 2013–2030 (14), the Mental\nand impact. WHO will additionally continue to collect health atlas 2020 (24), indicators provided as part of\nfeedback from international experts and health workers implementing WHO’s Intersectoral global action plan\nwho are familiar with using the mhGAP guideline. This on epilepsy and other neurological disorders 2022–2031",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "work",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Screening Cues The EML and EMLc includes products for MNS disorders\nComprehensive mental health action plan 2021–2030\nin the areas of psychotic disorders, mood disorders,\n(14), the Intersectoral global action plan on epilepsy\nanxiety, substance use and epilepsy (13,132). The\nand other neurological disorders 2022–2031 (3), the\nupdated recommendations for any psychotropic\nGlobal action plan on the public health response to\nmedicines will be used to inform the EML and EMLc\ndementia 2017–2025 (15), and the Global alcohol action\nand to promote affordable access to quality, safe and\nplan 2022–2030 (16).\neffective medicines for MNS disorders.\n16 https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre\n112\n5. Monitoring and evaluating\nthe impact of the guideline\nAfter the publication of this mhGAP guideline, where possible, including the Atlas: country resources\nWHO will continue to collect regular feedback from for neurological disorders (23), the Comprehensive\nimplementation activities to evaluate their usefulness mental health action plan 2013–2030 (14), the Mental\nand impact. WHO will additionally continue to collect health atlas 2020 (24), indicators provided as part of\nfeedback from international experts and health workers implementing WHO’s Intersectoral global action plan\nwho are familiar with using the mhGAP guideline. This on epilepsy and other neurological disorders 2022–2031 The eml and emlc includes products for mns disorders\ncomprehensive mental health action plan 2021–2030\nin the areas of psychotic disorders, mood disorders,\n(14), the intersectoral global action plan on epilepsy\nlo âu, su..."
}